Edwards Lifesciences Reports Second Quarter Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Edwards Lifesciences (EW) PT Raised to $120 at Oppenheimer
July 30, 2021 6:27 AM EDTOppenheimer analyst Suraj Kalia raised the price target on Edwards Lifesciences (NYSE: EW) to $120.00 (from $97.00) while maintaining an Outperform rating.
The analyst commented, "Edwards reported 2Q21 revenues of $1.38B vs. our/consensus' $1.29B/$1.28B estimates and guidance of $1.251.33B. TAVR revenues... More
Edwards Lifesciences (EW) Tops Q2 EPS by 9c; Raises Outlook
July 29, 2021 4:20 PM EDTEdwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.64, $0.09 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.
GUIDANCE:
Edwards Lifesciences sees FY2021 EPS of $2.07-$2.27, versus the consensus of $2.21.... More
